Literature DB >> 22415419

Effectiveness of sentinel lymph node intraoperative examination in 753 women with breast cancer: are we overtreating patients?

Mario Taffurelli1, Isacco Montroni, Donatella Santini, Monica Fiacchi, Simone Zanotti, Giampaolo Ugolini, Margherita Serra, Giancarlo Rosati.   

Abstract

OBJECTIVE: The goal of our study was to evaluate the sensitivity and specificity of sentinel lymph node biopsy (SLNB) frozen section (FS) examinations to detect metastatic lymph nodes and also its potential role in avoiding unnecessary demolitive axillary surgery.
BACKGROUND: SLNB is the standard of care in surgical oncology of the breast. Intraoperative evaluation of the SLN seems to achieve sufficient sensitivity for macrometastasis (Ma), leading to axillary lymph node dissection (ALND) only when strictly necessary. Is it equally as clear when to perform ALND if micrometastasis (Mi) or isolated tumor cells (ITCs) are detected?
METHODS: All consecutive patients from January 2005 to September 2010 operated on for breast cancer were prospectively enrolled. All patients underwent an FS SLNB. The sensitivity and specificity of SLN FSs in detecting Ma, Mi, and ITCs was calculated. All patients with Ma or Mi at FS underwent ALND. For all patients who underwent ALND, the number of metastatic non-SLNs was recorded and correlated to the size of the SLN metastasis.
RESULTS: A total of 753 patients were enrolled. FS examination had an overall 54% sensitivity and 100% specificity in detecting metastatic disease (Ma/Mi/ITCs). The sensitivity rises to 89% if only Mas were considered and to 64% if Mas and Mis were counted together. All patients with Mas or Mis detected at FS had a completion ALND during the same procedure (156/222). All patients with Mas detected at final pathology (16 false negatives, 2.6%) and 50 women with Mis or ITCs (119 false negatives, 20%) underwent a delayed ALND. When Mis or ITCs were detected in the SLN, only 8 of 73 (10.9%) and none of 4 (0%) patients, respectively, had at least 1 metastatic non-SLN after ALND. Two patients (2/460, 0.43%) who had negative SLNs showed local axillary recurrence. After a mean follow-up of 32 months, none of the 71 patients with Mis or ITCs who did not undergo a second operation showed local recurrence.
CONCLUSIONS: SLNB FS is highly effective in detecting the subgroup of patients who may benefit from completion ALND during the same surgical procedure. The role of Mi/ITCs in the SLN(s) is still unclear, but our data lean toward a less aggressive surgical approach.

Entities:  

Mesh:

Year:  2012        PMID: 22415419     DOI: 10.1097/SLA.0b013e31824def4e

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  5 in total

1.  Frozen section evaluation of breast carcinoma sentinel lymph nodes: a retrospective review of 1,940 cases.

Authors:  Justin S Poling; Theodore N Tsangaris; Pedram Argani; Ashley Cimino-Mathews
Journal:  Breast Cancer Res Treat       Date:  2014-10-16       Impact factor: 4.872

2.  A nomogram for predicting three or more axillary lymph node involvement before breast cancer surgery.

Authors:  Young-Joon Kang; Jung Hyun Park; Young Wook Ju; Kyoung-Eun Kim; Yumi Kim; Eunshin Lee; Han-Byoel Lee; Dong-Young Noh; Wonshik Han
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

3.  Should we examine sentinel lymph nodes during the operation?

Authors:  Akimitsu Yamada; Kazuaki Takabe
Journal:  Gland Surg       Date:  2012-11-01

4.  Can We Skip Intraoperative Evaluation of Sentinel Lymph Nodes? Nomogram Predicting Involvement of Three or More Axillary Lymph Nodes before Breast Cancer Surgery.

Authors:  Soo Kyung Ahn; Min Kyoon Kim; Jongjin Kim; Eunshin Lee; Tae-Kyung Yoo; Han-Byoel Lee; Young Joon Kang; Jisun Kim; Hyeong-Gon Moon; Jung Min Chang; Nariya Cho; Woo Kyung Moon; In Ae Park; Dong-Young Noh; Wonshik Han
Journal:  Cancer Res Treat       Date:  2017-01-25       Impact factor: 4.679

5.  Intraoperative Assessment of Sentinel Lymph Nodes in Breast Cancer Patients Post-Neoadjuvant Therapy.

Authors:  Willard Wong; Illana Rubenchik; Sharon Nofech-Mozes; Elzbieta Slodkowska; Carlos Parra-Herran; Wedad M Hanna; Fang-I Lu
Journal:  Technol Cancer Res Treat       Date:  2019-01-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.